Tristan Mañalac - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Tristan Mañalac's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Tristan Mañalac
Verified
Writer, Freelance
Philippines
Beats
Biography
Writer, Gaymer, Reluctant Fitness Partaker. Always anxious.
Pharma , Biotech , Medicine , Health Science
Crypto currency
Content
By Tristan Mañalac Verified| BioSpace Verified The FDA has three big decisions slated for the back half of April, two of which are for Regeneron’s blockbuster franchises. Read below for more. Following an initial rejection in October 2023, Regeneron and Sanofi are again trying to expand their anti-inflammatory antibody Dupixent into chronic spontaneous urticaria (CSU). The FDA’s decision is due on April 18. To support their bid for label expansion, the pharma partners submitted data from the Phase III LIBERTY-CUPID clinical program.
By Tristan Mañalac Verified| BioSpace Verified Senators Todd Young (R-IND) and Alex Padilla (D-CA) on Thursday filed a bill to help revitalize biotech in the U.S. as a key component of national security and economic productivity. The bill seeks to establish the National Biotechnology Coordination Office (NBCO), which would reside under the Office of the President and be responsible for harmonizing federal initiatives on biotech and for streamlining regulatory pathways.
By Tristan Mañalac Verified| BioSpace Verified Amgen’s anti-CD19 antibody Uplizna showed durable and deepening treatment effects for patients with generalized myasthenia gravis, maintaining improved function and disease activity through 1 year of follow-up, according to a data drop on Wednesday. Leerink analysts in a Wednesday note said that responses to Uplizna “progressively improved out to week 52,” adding that its end response is “comparable” to other drugs in the same therapeutic class, such as UCB’s Rystiggo and argenx’s Vyvgart.
Company Info
Freelance
Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.
De Pere, Wisconsin, United States